Connect with us


3 “Strong Buy” Momentum Stocks With More Room to Run

Finding stocks that are primed for gains is the key to success in the stock markets. Investors are naturally drawn to rising stocks – and while a particular equity’s past
Read More…
The post 3 "Strong Buy" Momentum Stocks With More Room to Run appeared.



Finding stocks that are primed for gains is the key to success in the stock markets. Investors are naturally drawn to rising stocks – and while a particular equity’s past performance won’t ensure its future gains, momentum is a good indicator for determining price movements.

Momentum trading – buying into stocks that shown solid gains and are likely to keep moving upward – is a sound strategy, but it does take some skill on the investor’s part. A savvy investor has to know how to differentiate between a true momentum stock and a fad.

The key is in the profile. Investors can look for stocks that offer a combination of three factors: strong, sustained gains; highly optimistic ratings from Wall Street’s analysts; and an upside potential that points toward maintenance of further gains.

Based on that profile, we’ve pulled up three momentum stocks using TipRanks’ database. Not only have all of the tickers amassed enough bullish calls from analysts to be given “Strong Buy” consensus ratings, but each could also see considerable share price appreciation.

Kulicke And Soffa Industries (KLIC)

Industrial tech is big business. Every digital device that we use, from smartphones and tablets to factory robots, depends on a linked series technical gadgets, giving tool makers and part manufacturers a sound foundation for true momentum. Kulicke and Soffa, KLIC, provides solutions for electronic assembly in a variety of industries, including the automotive, communications, computing, and consumer goods sectors. The company’s product portfolio includes a range of tools for advanced packaging, electronics assembly, lithography, and wire bonding.

In the most recent quarterly report, for fiscal Q1 of 2021, KLIC reported $267.9 million at the top line, up 85% year-over-year. Income also gained, with EPS at 77 cents. This was more than triple the year-ago quarter’s 21 cents.

The company attributed the strong quarter to increased demand in the second half of calendar year 2020. Looking forward, management expects to see continued growth, and set fiscal Q2 guidance at $300 million in revenue (+/- $20 million) and EPS of 88 cents (+/- 10%).

Combining industry and high tech has been good for KLIC, whose stock has gained an impressive 143% in the past 12 months.

Covering KLIC for B. Riley Securities, 5-star analyst Craig Ellis believes that the path is clear for continued momentum.

“We boost F21&F22 estimates… with three factors sustaining a Buy. First, upstream secular and cyclical chip fundamentals should drive strong growth deep into C22, propelling upside estimate potential. Second, we believe new mini-LED and Advanced Packaging products remain on track for $100M of incremental F22 sales and greater LT. Third, near-term GM headwinds look temporal, and we expect progress toward 47.5% through F21/22 but model more conservatively,” Ellis noted. "

To this end, Ellis gives KLIC shares a Buy rating, and his $75 price target indicates confidence in a 26% upside for the coming year. (To watch Ellis’ track record, click here)

While there are only three reviews on record for KLIC, they are unanimous – to Buy the stock. This shows that Ellis’ upbeat outlook is no outlier, and gives the stock its Strong Buy analyst consensus rating. (See KLIC stock analysis on TipRanks)

ASML Holding (ASML)

We'll stick with the high tech sector, and look at another provider of the tools that digital equipment manufacturers cannot live without. Specifically, ASML Holding designs and builds photolithography equipment, which is vital in the production of semiconductor chips. The company’s tools use optical imaging to impress circuit patterns on silicon wafers. This is the essential process in chip making, and ASML Holding has a 67% market share in its industry.

It’s a niche industry, but it’s one of the few that truly does make the world go ‘round.' And ASML has profited mightily from its leading position. The stock is up 131% over the past 12 months.

The Netherlands-based company posted these share gains against a background of rising revenues. The top line has increased in each of the last four quarter, reaching 4.4 billion Euro (US$5.26 billion) in Q1 of 2021. EPS came in at 3.21 Euro (US$3.86), more than triple the $1.02 recorded in 1Q20.

In the first quarter, the company reported high customer demand, with bookings reaching 4.7 billion Euro (US$5.69 billion). Demand was especially strong in the Installed Base segment, as existing customers moved to upgrade software to meet their own increasing demand. In the background here is a semiconductor chip market that is seeing both increased demand and a severe supply shortage, as customers are racing to meet orders backlogged during the pandemic shutdowns and suppliers are racing to ramp up production from pandemic-induced low levels.

With all of that in the background, BofA analyst Didier Scemama selected ASML as his top large cap pick in European semiconductors.

“We expect ASML to benefit from multiple drivers incl. 1) Healthy competition among ASML customer base, confirming ASML status as a “weapon dealer” in the Intel/TSMC/Samsung process “war”, 2) Silicon sovereignty, driving EU/US to incentivize chipmakers to re-shore semis production and adding to China’s 2025 semis self-sufficiency ambitions, 3) EUV cycle: we model 21% sales CAGR ’20-25 driven by multiple, concurrent high-growth end-markets,” Scemama opined.

Unsurprisingly, Scemama rates ASML a Buy, and his price target of $806 suggests an upside of 20% in the next 12 months. (To watch Scemama’s track record, click here)

If we step back and look at the bigger picture, we can see that overall the stock has a ‘Strong Buy’ analyst consensus rating. In the last three months, the stock has received 4 Buy ratings and just 1 Hold. (See ASML stock analysis on TipRanks)

Ashland (ASH)

The third momentum pick, Ashland, inhabits the specialty chemical niche, producing a variety of necessary ingredients for a range of industries. The company products include adhesives, emulsifiers, and preservatives – to name just a few categories – and are used in the construction, coating, energy, food and beverage, health and wellness, packaging, pharmaceutical, and transportation industries. In short, Ashland is diversified.

That diversification has helped the company to weather the corona crisis, and propelled it to a share gain of 62% in the last 12 months. These gains came even as the pandemic – and the associate market, production, and supply disruptions – pushed 2020 annual revenues down to $2.3 billion from the prior year’s $2.5 billion.

In the most recent quarter, Q1 of fiscal 2021, Ashland reported $552 million at the top line. This was up 3.5% year-over-year, and beat the pre-earnings estimates by 1.6%. EPS came in at 99 cents per share, nearly double the 52 cents reported one year earlier – and 25% above expectations.

Analyst John McNulty, weighing in on Ashland from BMO Capital, sees a clear path forward for the company.

“We see solid upside to margins over the next few years, a focus on innovation/growth helping the top line and increased cash conversion... ASH continues to work towards improving its cost structure while also working to re-accelerate its top-line growth... Assuming management continues to execute and margins improve to 25%+ while the top-line growth improves to a mid-single-digit level, ASH should see earnings growth that significantly exceeds expectations while also enjoying multiple expansion.” the analyst commented.

McNulty rates ASH shares as Outperform (i.e. Buy), and his $115 price target implies a one-year upside of 22%. (To watch McNulty’s track record, click here)

Wall Street’s analysts can be a contentious lot – but when they agree on a stock, it’s a positive sign for investors to take note. That’s the case here, as all of the recent reviews on ASH are to Buy, making the consensus rating a unanimous Strong Buy. (See ASH stock analysis on TipRanks)

To find good ideas for momentum stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

The post 3 "Strong Buy" Momentum Stocks With More Room to Run appeared first on TipRanks Financial Blog.

Read More

Continue Reading


4 Biotech Stocks For Your August 2021 Watchlist

Investors could be shifting their focus to biotech stocks, should you do the same?
The post 4 Biotech Stocks For Your August 2021 Watchlist appeared first on Stock Market News, Quotes, Charts and Financial Information |



top biotech stocks to watch

4 Top Biotech Stocks To Watch This Month

As investors look for the next lucrative industry in the stock market, biotech stocks would often be in sight. It may not be the largest industry nor the most exciting, but it does boast some of the highest potential for returns. For example, a biotech company posting positive clinical trial results or gaining FDA approval will likely see big gains. Meanwhile, a delay or negative results could send a company’s stock in the wrong direction. 

We need to look no further than Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) when it comes to the importance health care brings to the table. Out of the blue, we were struck by a global pandemic that has changed everyone’s lives. This has then made people realize the important roles that biotech stocks play in crucial times like this. Demand for coronavirus vaccines remains high as fears of the delta variant escalate. With the potential need for booster shots in discussion, Moderna and Pfizer are able to raise the prices of their jabs in their latest European Union (EU) supply contracts. With that being said, are you also on the lookout for the top biotech stocks in the stock market today

Top Biotech Stocks To Buy [Or Sell] In August 2021

BioNTech SE

Firstly, we have the German biotech company, BioNTech. Put simply, it develops and commercializes immunotherapies for cancer and other infectious diseases. Over the past year, the company became known globally through its partnership with Pfizer to develop the coronavirus vaccine that is being used today. BNTX stock has skyrocketed over the past month due to fears of coronavirus escalating. It has risen over 45% just within the one-month period. 

In July, the company along with Pfizer announced that the U.S. government purchased an additional 200 million doses of its coronavirus vaccine. With this, the total number of doses supplied by the companies to the U.S. government will be at 500 million. These additional doses are expected to be delivered from October 2021 through April 2022. The U.S. government’s confidence in the vaccine puts both companies in a favorable position. After all, vaccines have been and will remain critical in protecting lives against the pandemic.

On another note, BioNTech has also announced the launch of its Malaria project last Monday. This project aims to develop a well-tolerated and highly effective Malaria vaccine and implement sustainable vaccine supply solutions on the African continent. Its efforts will include cutting-edge research and innovation, investments in vaccine development, and establishing manufacturing facilities across the continent. Given the company’s track record in tackling infectious diseases, there are reasons to believe this will be successful long-term. All things considered, would you consider buying BNTX stock?

biotech stocks (BNTX stock)
Source: TD Ameritrade TOS

Read More

Zai Lab Ltd

China-based biopharmaceutical company Zai Lab focuses on developing and commercializing therapeutics in oncology, autoimmune and infectious diseases. As of now, it has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. A few examples would be Niraparib, Zl-2103, ZL-1101, and others. 

Last Tuesday, the company and Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) announced that patient enrollment in the ATTACK Phase 3 registrational clinical trial of sulbactam-durlobactam is now complete. This will be the largest antibiotic-resistant, pathogen-specific registrational trial conducted globally. Also, it is the first to focus specifically on carbapenem-resistant Acinetobacter infections. Should top-line data be announced in the coming months, it would be a huge step for both companies. 

Besides that, Zai Lab also collaborated with MacroGenics (NASDAQ: MGNX) to develop and commercialize preclinical bispecific antibodies in oncology during its second quarter. Under the terms of the agreement, Zai Lab receives commercial rights in China, Japan, and Korea while MacroGenics will have the rights in all other territories. Now, the collaboration leverages both companies’ unique research capabilities and gives Zai Lab access to MacroGenics’ proprietary technologies to expand its innovative oncology portfolio. With these in mind, would ZLAB stock be a top biotech stock to buy?

best biotech stocks (ZLAB stock)
Source: TD Ameritrade TOS

[Read More] Best Communication Stocks To Watch Right Now

Vertex Pharmaceuticals Incorporated

Next up, we may have one of the top biotech companies that have flown under the radar of many investors, Vertex. For the uninitiated, the company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF). Its marketed medicines are ORKAMBI and KALYDECO. 

Just last week, Vertex announced that it will initiate a Phase 3 development program for the new once-daily investigational triple combination of VX-121/tezacaftor/VX-561(deutivacaftor) in the second half of 2021. The data from its Phase 2 study were mostly encouraging. Hence, the company aims to develop a more effective treatment regimen with the potential to restore cystic fibrosis transmembrane conductance regulator function in people with CF to even higher levels than currently achievable. 

During its second quarter, Vertex showed continued, and significant growth in its CF franchise. Its product revenues came in at $1.79 billion, an increase of 18% year-over-year. Thus, allowing the company to raise its full-year guidance for product revenues to $7.2 to $7.4 billion. Moreover, Vertex has also made important progress with its pipeline programs with five programs in mid to late-stage clinical trials. So, would you consider investing in VRTX stock on the dip? 

VCYT stock
Source: TD Ameritrade TOS

[Read More] Top Gaming Stocks To Buy Now? 4 Names To Watch

Veracyte Inc

Veracyte is a genomic diagnostics company. The company utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, and produces genomic tests. The genomic tests include Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier, and Afirma Xpression Atlas. 

Investors could be watching VCYT stock following the company’s recent new data announcement and second-quarter earnings report. So, Veracyte’s new data suggest the Decipher Prostate Biopsy genomic classifier (GC) may help guide treatment decisions for prostate cancer patients who are candidates for active surveillance (AS). It has found evidence that Decipher scores predict time to definitive treatment and time to treatment failure among men with early-stage prostate cancer. With this, it fills a critical gap in prostate cancer treatment. 

On the other hand, its second-quarter financial results showed significant momentum with particularly strong growth in its thyroid and urologic cancer product lines. Its total revenue was $55.1 million, up by 166% year-over-year. Meanwhile, its total volume of genomic tests grew to 20,856, an increase of 215% compared to the prior year’s quarter. If we take into account the pending HalioDx acquisition, it will further fuel Veracyte’s global cancer diagnostics growth and leadership. So, would you be watching VCYT stock right now?

VCYT stock
Source: TD Ameritrade TOS

The post 4 Biotech Stocks For Your August 2021 Watchlist appeared first on Stock Market News, Quotes, Charts and Financial Information |

Read More

Continue Reading


Best Cheap Stocks To Buy Now? 4 Tech Stocks To Know

Could these tech stocks be worth betting on now?
The post Best Cheap Stocks To Buy Now? 4 Tech Stocks To Know appeared first on Stock Market News, Quotes, Charts and Financial Information |



best cheap stocks to buy now (tech stocks)

Are These The Top Tech Stocks To Buy This Week?

With the current momentum in the broader stock market, investors could be considering tech stocks among other growth areas now. For starters, companies across the board continue to see stellar growth this earnings season. According to global market data analysis firm Refinitiv, overall earnings across the S&P 500 are expected to rise 76% year-over-year. Notably, this would mark its fastest growth since 2009. With the economy having gone into full swing for the past quarter, this would make sense. Now, tech stocks, in particular, could be well-positioned to leverage the current market conditions.

For the most part, the industry does not seem to be slowing down anytime soon as well. Evidently, some of the biggest names in tech known as FAANG stocks reported solid earnings over the past few weeks. To highlight, Amazon (NASDAQ: AMZN) saw significant growth across its wide portfolio. Accordingly, it posted sizable year-over-year jumps of 87% in ad revenue and 37% in cloud revenue. Elsewhere, Microsoft (NASDAQ: MSFT) is reportedly looking to invest in Oyo, one of India’s most valuable startups. Backing the leading budget hotel chain operator in the region would be a unique play by Microsoft. Nonetheless, the company appears keen to broaden its investments and current portfolio.

Overall, these are but two instances of the constant growth in the tech industry now. Most would argue that the stock market today is home to plenty more upcoming tech stocks worth knowing. Should all this have you interested to invest in some yourself, here are four to watch this week.

Best Tech Stocks To Buy [Or Sell] Today

Lam Research Corporation

Lam Research is a tech company that focuses on its innovative wafer fabrication equipment and services. Its products allow chipmakers to build smaller, faster, and better-performing electronic devices. It combines its superior systems engineering capabilities with its unwavering commitment to customer success. In fact, nearly every advanced chip is built with the company’s technology. LRCX stock currently trades at $641.80 as of Monday’s closing bell and is up by over 68% in the past year. On July 28, 2021, the company reported its June 2021 quarter financials.

Firstly, the company posted revenue of $4.15 billion for the quarter, increasing by over 45% year-over-year. Secondly, the company also saw its earnings per share increase by over 70% year-over-year at diluted earnings per share of $7.98. Lam Research says that strong semiconductor demand and rising device complexity are driving higher levels of wafer fabrication equipment investment. It also says that its edge in technology and collaboration with customers positions the company to extend its leadership across all its market segments. The company also ended the quarter with $6 billion in cash and cash equivalents. Given this piece of news, will you consider adding LRCX stock to your watchlist?

top tech stocks (LRCX stock)
Source: TD Ameritrade TOS

Read More

Virgin Galactic Holdings Inc.

Moving on, we have Virgin Galactic, a spaceflight company with headquarters in California and operations in New Mexico. The company runs a commercial spaceflight business, with regular paid passenger service flights scheduled to begin in 2022. SPCE stock closed Monday’s trading session up 6.30% at $31.87 a share. The company will be reporting its second-quarter 2021 financials on August 5, 2021, after the market closes.

On July 11, 2021, company founder Richard Branson and three other employees rode on a flight as passengers, marking the first time a spaceflight company founder has traveled on his own ship into outer space. This successful flight is a landmark achievement for the company and a historic moment for the new commercial space industry. The team behind this successful flight will also open the door for greater access to space for an industry that is still in its infancy. All things considered, will you buy SPCE stock ahead of it popularizing commercial spaceflight?

best tech stocks (SPCE stock)
Source: TD Ameritrade TOS

[Read More] 4 Top E-Commerce Stocks To Consider Buying Right Now

Roblox Corporation

Roblox is a tech company that focuses on video game development. Its tech platform enables billions of users to play, learn and communicate. Furthermore, it empowers its global community of developers who in turn produce its own immersive multiplayer experiences using Roblox Studio. In essence, the company is one of the top online entertainment platforms for audiences under the age of 18. Shares of RBLX stock closed Monday’s trading session at $78.31 apiece.

Last month, the company announced a strategic partnership that will bring more Sony Music (NYSE: SONY) recording artists to the Roblox metaverse. Both companies will work together to develop innovative music experiences for the Roblox community. It will also offer a range of new commercial opportunities for Sony Music artists to reach new audiences and generate new revenue streams around virtual entertainment. The agreement builds on an existing relationship between the two companies that included previous collaborations with big names such as Lil Nas X’s hit virtual performance on Roblox in November 2020. With that being said, will you consider RBLX stock a top tech stock to add to your radar this month?

top tech stocks (RBLX stock)
Source: TD Ameritrade TOS

[Read More] Best Stocks To Invest In 2021? 4 Dividend Stocks To Watch

ContextLogic Inc.

Another emerging name in the tech space to consider now would be ContextLogic or Wish for short. In brief, the company operates via its proprietary e-commerce platform, Wish. Through a combination of tech and data science, Wish helps to facilitate transactions and interactions between buyers and sellers. The Wish platform provides consumers with an “innovative discovery-based mobile shopping experience”. Accordingly, this would appeal to homebound consumers throughout the current pandemic. In terms of scale, Wish serves millions of consumers from over 100 countries across the globe. The company accomplishes this via its network of over half a million merchants.

Now, WISH stock ended Monday’s trading day up a modest 4.37% at $10.41 a share. Could it be worth investing in now? If anything, the company’s latest earnings figures could provide a clearer understanding on this end. Back in May, the company raked in total revenue of $772 million for the quarter. This marks a solid 75% year-over-year surge. Moreover, Wish also saw its core marketplace revenue per active buyer surge by 76% over the same time. Not to mention, the company’s logistics revenue reportedly quadrupled year-over-year. With Wish set to report its second-quarter fiscal next week, would you consider WISH stock a top cheap tech stock to watch now?

WISH stock
Source: TD Ameritrade TOS

The post Best Cheap Stocks To Buy Now? 4 Tech Stocks To Know appeared first on Stock Market News, Quotes, Charts and Financial Information |

Read More

Continue Reading

Spread & Containment

Top Stocks To Watch This Week? 3 Fintech Stocks Making Headlines

Should investors be watching these top fintech names now?
The post Top Stocks To Watch This Week? 3 Fintech Stocks Making Headlines appeared first on Stock Market News, Quotes, Charts and Financial Information |




top stocks to watch this week (fintech stocks)

Are These Best Fintech Stocks To Buy Right Now?

Financial technology, or fintech for short, is an increasingly vital industry in the world today. By extension, this would make fintech stocks increasingly relevant in the stock market today. This would be the case as fintech companies enable contactless payments along with other financial services directly accessible from consumers’ smartphones. When you couple this with the current pandemic, it is easy to understand why fintech has skyrocketed in popularity. With signs of another wave of coronavirus infections incoming, some would argue that fintech stocks could continue to thrive.

In fact, Mastercard (NYSE: MA) CFO Sachin Mehra believes that consumer reliance on fintech services could grow past pre-pandemic levels. Just last week, Mehra cited Mastercard’s second-quarter earnings figures as a key indicator of this. In detail, the company saw its gross dollar volume, which reflects purchase activity, increase by 34% year-over-year. This added up to a whopping $619 billion. More importantly, it also marks a 27% increase from the same quarter in 2019. Mehra also highlighted that we “haven’t even seen travel come back to the levels we used to see pre-pandemic.” In theory, this would indicate that the fintech industry could potentially have more room to run moving forward.

For instance, we could look at the likes of Fiserv (NASDAQ: FISV) and Visa (NYSE: V). Both companies are notable players in the industry today. Likewise, they continue to make massive plays on the operational end, on top of the current industry tailwinds. Overall, Fiserv recently made significant expansions to its digital banking services and Visa acquired fintech software firm Currencycloud in the U.K. last month. Given all of the activity in this section of the stock market, you might be keen on top fintech stocks yourself. In that case, here are three names to know now.

Best Fintech Stocks To Watch Right Now

Square Inc.

To begin with, we will be taking a look at Square Inc. The California-based fintech company is a titan in the industry today. In short, it offers a wide variety of financial services and digital payment solutions. Through all of this, Square primarily caters to the needs of businesses of varying sizes. The likes of which rely on the company’s offerings to manage their operations, access financing, and improve their market reach. On the consumer front, Square’s flagship Cash App smartphone service boasts over 40 million monthly active users.

After considering all of this, many would see SQ stock as a viable play on the current fintech boom. Evidently, the company’s shares are already looking at massive gains of over 540% since its pandemic-era low. Regardless, Square continues to press forward on all fronts now. Earlier today, the company released its second-quarter financial results ahead of schedule. In it, Square posted stellar figures across the board. The company saw gross payment volume (GPV) for the quarter add up to $42.8 billion, marking a significant 87% year-over-year leap. As a result, Square also reported year-over-year surges of 143% in total revenue and 94% in Cash App gross profit. All in all, user demand for Square’s services seems to be holding strong.

At the same time, the company is also planning to acquire Afterpay (OTCMKTS: AFTPF), an Australian fintech firm, for $29 billion. With this move, Square would be making a significant expansion into the “Buy Now, Pay Later” (BNPL) service space. Given that Afterpay is the pioneering name in this space, this could be a win for Square. Now, with Square looking to integrate Afterpay into its Cash App, would you be buying SQ stock?

top fintech stocks (SQ stock)
Source: TD Ameritrade TOS

Read More

Apple Inc.

Following that, we have Apple Inc. Sure, most would not immediately think about Apple when discussing fintech. However, the consumer tech giant also has a hand in the industry now. This would be mainly through its Apple Pay division. In brief, Apple Pay is a mobile payment and digital wallet service. As you can imagine, it allows Apple users to make secure payments via its devices. Given the popularity of Apple’s wares, this would provide the company with a sizable addressable market.

Now, the question for today is, would AAPL stock be a top fintech stock to consider? Well, for one thing, the company does not seem to be sitting idly by on this front. Just last month, news broke of Apple reportedly partnering up with Goldman Sachs (NYSE: GS). The duo is now working to bring the Apple Pay Later service to Apple Pay’s users. As the name suggests, it is a BNPL service as well. Similar to our previous entry, Apple appears to be well aware of the shifting needs in the consumer fintech market. Through the current deal, Goldman Sachs will act as the lender for installment loans. Accordingly, Apple Pay users will be able to spread their payments across four interest-free transactions across a two-week timespan.

Arguably, this could be a smart play on Apple’s end now, especially with the global chip shortage. Ideally, even if the company’s hardware supplies take a hit, it can still support growth via services such as Apple Pay. With all this in mind, will you be keeping an eye on AAPL stock?

fintech stocks (aapl stock)
Source: TD Ameritrade TOS

[Read More] Best Stocks To Buy Right Now? 5 Aerospace Stocks To Know

Affirm Holdings Inc.

Topping off our list today is BNPL player Affirm Holdings Inc. According to Affirm, its customers can finance purchases at the point of sale without worrying about late or hidden fees. Through its services, the company now caters to over 5.4 million consumers. With that in mind, could AFRM stock be worth buying at its current price point?

If anything, analysts appear to believe so. Just last month, both CNBC’s Jim Cramer and Truist (NYSE: TFC) analyst Andrew Jeffrey had good things to say about AFRM stock. Firstly, Cramer highlighted the company in the lightning round segment of his show saying, “I am a buyer at the $56 level.” Secondly, Jeffrey hit AFRM stock with a buy rating and an $82 price target. This would indicate a potential 45% upside from its current price of $56.32 as of last week’s closing bell. According to the analyst, Affirm’s current position in the BNPL industry is worth noting given its “superior merchant integrations and complex underwriting abilities”. The likes of which supposedly differentiate it from the current competition.

Moreover, the company also recently expanded its partnership with e-commerce juggernaut Shopify (NYSE: SHOP). As of last month, Shop Pay Installments is now exclusively powered by Affirm. Because of this, all eligible Shopify merchants in the U.S. now have access to the BNPL solution. Having read all this, would you consider adding AFRM stock to your August watchlist?

Source: TD Ameritrade TOS

The post Top Stocks To Watch This Week? 3 Fintech Stocks Making Headlines appeared first on Stock Market News, Quotes, Charts and Financial Information |

Read More

Continue Reading